BIOMARIN PHARMACEUTICAL INC Net Income (Loss) Available to Common Stockholders, Basic
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Net Income (Loss) Available to Common Stockholders, Basic of $44.76 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-06
- BIOMARIN PHARMACEUTICAL INC net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was $44.76M, a 81.39% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was $105.53M, a 43.17% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$46.57M, a 137.28% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$30.74M, a 128.98% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC net income (loss) available to common stockholders, basic for fiscal 2025 was $348.90M, a 18.26% decline from fiscal 2024.
- BIOMARIN PHARMACEUTICAL INC net income (loss) available to common stockholders, basic for fiscal 2024 was $426.86M, a 154.62% increase from fiscal 2023.
- BIOMARIN PHARMACEUTICAL INC net income (loss) available to common stockholders, basic for fiscal 2023 was $167.65M, a 18.43% increase from fiscal 2022.
- BIOMARIN PHARMACEUTICAL INC net income (loss) available to common stockholders, basic for fiscal 2022 was $141.56M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 12 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $44.76M 10-Q · filed 2026-08-06 | $150.29M 10-Q · filed 2026-08-06 | $103.72M derived: sum of 3 quarters · filed 2026-08-06 | $72.97M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $105.53M 10-Q · filed 2026-05-05 | $58.95M derived: sum of 2 quarters · filed 2026-05-05 | $28.21M derived: sum of 3 quarters · filed 2026-05-05 | $268.74M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | -$46.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$77.32M derived: sum of 2 quarters · filed 2026-02-26 | $163.22M derived: sum of 3 quarters · filed 2026-08-06 | $348.90M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | -$30.74M 10-Q · filed 2025-10-28 | $209.79M derived: sum of 2 quarters · filed 2026-08-06 | $395.47M 10-Q · filed 2025-10-28 | $520.42M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | $240.53M 10-Q · filed 2026-08-06 | $426.22M 10-Q · filed 2026-08-06 | $551.16M derived: sum of 3 quarters · filed 2026-08-06 | $657.24M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $185.69M 10-Q · filed 2026-05-05 | $310.63M derived: sum of 2 quarters · filed 2026-05-05 | $416.71M derived: sum of 3 quarters · filed 2026-05-05 | $523.88M derived: sum of 4 quarters · filed 2026-05-05 | |||
| 2024-12-31 | $124.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $231.02M derived: sum of 2 quarters · filed 2026-02-26 | $338.20M derived: sum of 3 quarters · filed 2026-02-26 | $426.86M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $106.08M 10-Q · filed 2025-10-28 | $213.25M derived: sum of 2 quarters · filed 2025-10-28 | $301.92M 10-Q · filed 2025-10-28 | $322.29M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-06-30 | $107.17M 10-Q · filed 2025-08-05 | $195.84M 10-Q · filed 2025-08-05 | $216.21M derived: sum of 3 quarters · filed 2026-02-26 | $256.59M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-03-31 | $88.66M 10-Q · filed 2025-05-02 | $109.04M derived: sum of 2 quarters · filed 2026-02-26 | $149.41M derived: sum of 3 quarters · filed 2026-02-26 | $205.46M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2023-12-31 | $20.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $60.75M derived: sum of 2 quarters · filed 2026-02-26 | $116.79M derived: sum of 3 quarters · filed 2026-02-26 | $167.65M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $40.38M 10-Q · filed 2024-10-31 | $96.42M derived: sum of 2 quarters · filed 2024-10-31 | $147.27M 10-Q · filed 2024-10-31 | $147.02M derived: sum of 4 quarters · filed 2025-02-24 | |||
| 2023-06-30 | $56.04M 10-Q · filed 2024-08-05 | $106.89M 10-Q · filed 2024-08-05 | $106.64M derived: sum of 3 quarters · filed 2025-02-24 | $99.99M derived: sum of 4 quarters · filed 2025-02-24 | |||
| 2023-03-31 | $50.85M 10-Q · filed 2024-04-26 | $50.60M derived: sum of 2 quarters · filed 2025-02-24 | $43.95M derived: sum of 3 quarters · filed 2025-02-24 | $71.61M derived: sum of 4 quarters · filed 2025-02-24 | |||
| 2022-12-31 | -$249.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | -$6.90M derived: sum of 2 quarters · filed 2025-02-24 | $20.76M derived: sum of 3 quarters · filed 2025-02-24 | $141.56M 10-K · filed 2025-02-24 | |||
| 2022-09-30 | -$6.65M 10-Q · filed 2023-11-02 | $21.01M derived: sum of 2 quarters · filed 2023-11-02 | $141.81M 10-Q · filed 2023-11-02 | $83.91M derived: sum of 4 quarters · filed 2023-11-02 | |||
| 2022-06-30 | $27.66M 10-Q · filed 2023-08-02 | $148.46M 10-Q · filed 2023-08-02 | $90.56M derived: sum of 3 quarters · filed 2023-08-02 | $54.07M derived: sum of 4 quarters · filed 2023-08-02 | |||
| 2022-03-31 | $120.80M 10-Q · filed 2023-04-28 | $62.90M derived: sum of 2 quarters · filed 2023-04-28 | $26.41M derived: sum of 3 quarters · filed 2023-04-28 | $39.35M derived: sum of 4 quarters · filed 2023-04-28 | |||
| 2021-12-31 | -$57.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$94.39M derived: sum of 2 quarters · filed 2023-02-27 | -$81.45M derived: sum of 3 quarters · filed 2023-02-27 | -$64.08M 10-K · filed 2023-02-27 | |||
| 2021-09-30 | -$36.49M 10-Q · filed 2022-10-28 | -$23.55M derived: sum of 2 quarters · filed 2022-10-28 | -$6.18M 10-Q · filed 2022-10-28 | $10.85M derived: sum of 4 quarters · filed 2023-02-27 | |||
| 2021-06-30 | $12.94M 10-Q · filed 2022-08-04 | $30.31M 10-Q · filed 2022-08-04 | $47.34M derived: sum of 3 quarters · filed 2023-02-27 | $832.14M derived: sum of 4 quarters · filed 2023-02-27 | |||
| 2021-03-31 | $17.37M 10-Q · filed 2022-04-29 | $34.40M derived: sum of 2 quarters · filed 2023-02-27 | $819.20M derived: sum of 3 quarters · filed 2023-02-27 | ||||
| 2020-12-31 | $17.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $801.83M derived: sum of 2 quarters · filed 2023-02-27 | $854.03M 10-K · filed 2023-02-27 | $859.10M 10-K · filed 2021-02-26 | |||
| 2020-09-30 | $784.80M 10-Q · filed 2021-10-29 | $837.00M 10-Q · filed 2021-10-29 | |||||
| 2020-03-31 | $81.38M 10-Q · filed 2021-04-30 | $96.41M derived: sum of 2 quarters · filed 2022-02-25 | $151.44M derived: sum of 3 quarters · filed 2022-02-25 | ||||
| 2019-12-31 | $15.02M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $70.06M derived: sum of 2 quarters · filed 2022-02-25 | -$23.85M 10-K · filed 2022-02-25 | ||||
| 2019-09-30 | $55.04M 10-Q · filed 2020-11-06 | -$38.87M 10-Q · filed 2020-11-06 | |||||
| 2019-03-31 | -$56.47M 10-Q · filed 2020-05-01 | -$60.12M derived: sum of 2 quarters · filed 2021-02-26 | -$72.74M derived: sum of 3 quarters · filed 2021-02-26 | ||||
| 2018-12-31 | -$3.65M derived: 10-K 12 month − 10-Q/A 9 month · filed 2021-02-26 | -$16.27M derived: sum of 2 quarters · filed 2021-02-26 | -$77.21M 10-K · filed 2021-02-26 | ||||
| 2018-09-30 | -$12.62M 10-Q/A · filed 2019-11-04 | -$73.56M 10-Q/A · filed 2019-11-04 | |||||
| 2018-03-31 | -$44.15M 10-Q · filed 2019-04-29 | -$95.54M derived: sum of 2 quarters · filed 2020-02-27 | -$108.07M derived: sum of 3 quarters · filed 2020-02-27 | ||||
| 2017-12-31 | -$51.39M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | -$63.92M derived: sum of 2 quarters · filed 2020-02-27 | -$117.04M 10-K · filed 2020-02-27 | ||||
| 2017-09-30 | -$12.53M 10-Q · filed 2017-10-31 | -$65.65M 10-Q · filed 2017-10-31 | |||||
| 2017-03-31 | -$16.29M 10-Q · filed 2018-04-27 | -$107.01M derived: sum of 2 quarters · filed 2019-02-28 | -$144.44M derived: sum of 3 quarters · filed 2019-02-28 | ||||
| 2016-12-31 | -$90.72M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | -$128.15M derived: sum of 2 quarters · filed 2019-02-28 | -$630.21M 10-K · filed 2019-02-28 | ||||
| 2016-09-30 | -$37.42M 10-Q · filed 2017-10-31 | -$42.80M 10-Q · filed 2016-11-03 | -$539.49M 10-Q · filed 2017-10-31 | -$551.50M 10-Q · filed 2016-11-03 | |||
| 2015-12-31 | $68.62M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | -$22.31M derived: sum of 2 quarters · filed 2018-02-26 | -$104.30M derived: sum of 3 quarters · filed 2018-02-26 | -$171.80M 10-K · filed 2018-02-26 | |||
| 2015-09-30 | -$90.93M 10-Q · filed 2016-11-03 | -$172.91M derived: sum of 2 quarters · filed 2016-11-03 | -$240.42M 10-Q · filed 2016-11-03 | -$310.21M derived: sum of 4 quarters · filed 2017-02-27 | |||
| 2015-06-30 | -$81.99M 10-Q · filed 2015-08-05 | -$149.49M 10-Q · filed 2015-08-05 | -$219.29M derived: sum of 3 quarters · filed 2017-02-27 | -$211.84M derived: sum of 4 quarters · filed 2017-02-27 | |||
| 2015-03-31 | -$67.50M 10-Q · filed 2015-05-05 | -$137.30M derived: sum of 2 quarters · filed 2017-02-27 | -$129.85M derived: sum of 3 quarters · filed 2017-02-27 | -$163.35M derived: sum of 4 quarters · filed 2017-02-27 | |||
| 2014-12-31 | -$69.80M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | -$62.35M derived: sum of 2 quarters · filed 2017-02-27 | -$95.85M derived: sum of 3 quarters · filed 2017-02-27 | -$133.97M 10-K · filed 2017-02-27 | |||
| 2014-09-30 | $7.45M 10-Q · filed 2015-11-02 | -$26.06M derived: sum of 2 quarters · filed 2015-11-02 | -$64.17M 10-Q · filed 2015-11-02 | ||||
| 2014-06-30 | -$33.50M 10-Q · filed 2015-08-05 | -$71.62M 10-Q · filed 2015-08-05 | |||||
| 2014-03-31 | -$38.12M 10-Q · filed 2015-05-05 | ||||||
| 2013-09-30 | -$53.02M 10-Q · filed 2014-10-28 | -$74.55M derived: sum of 2 quarters · filed 2014-10-28 | -$114.36M 10-Q · filed 2014-10-28 | ||||
| 2013-06-30 | -$21.53M 10-Q · filed 2014-07-31 | -$61.34M 10-Q · filed 2014-07-31 | |||||
| 2013-03-31 | -$39.81M 10-Q · filed 2014-05-02 | ||||||
| 2012-12-31 | -$114.35M 10-K · filed 2013-02-26 | ||||||
| 2012-06-30 | -$32.01M 10-Q · filed 2013-07-29 | -$55.98M 10-Q · filed 2013-07-29 | -$82.71M derived: sum of 3 quarters · filed 2013-07-29 | -$100.37M derived: sum of 4 quarters · filed 2013-07-29 | |||
| 2012-03-31 | -$23.97M 10-Q · filed 2012-04-30 | -$50.71M derived: sum of 2 quarters · filed 2013-02-26 | -$68.36M derived: sum of 3 quarters · filed 2013-02-26 | -$73.44M derived: sum of 4 quarters · filed 2013-02-26 | |||
| 2011-12-31 | -$26.73M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | -$44.39M derived: sum of 2 quarters · filed 2013-02-26 | -$49.47M derived: sum of 3 quarters · filed 2013-02-26 | -$53.84M 10-K · filed 2013-02-26 | |||
| 2011-09-30 | -$17.65M 10-Q · filed 2011-10-31 | -$22.73M derived: sum of 2 quarters · filed 2011-10-31 | -$27.10M 10-Q · filed 2011-10-31 | -$39.29M derived: sum of 4 quarters · filed 2013-02-26 | |||
| 2011-06-30 | -$5.08M 10-Q · filed 2011-08-01 | -$9.45M 10-Q · filed 2011-08-01 | -$21.64M derived: sum of 3 quarters · filed 2013-02-26 | $195.70M derived: sum of 4 quarters · filed 2013-02-26 | |||
| 2011-03-31 | -$4.37M 10-Q · filed 2012-04-30 | -$16.56M derived: sum of 2 quarters · filed 2013-02-26 | $200.77M derived: sum of 3 quarters · filed 2013-02-26 | $200.30M derived: sum of 4 quarters · filed 2013-02-26 | |||
| 2010-12-31 | -$12.19M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $205.15M derived: sum of 2 quarters · filed 2013-02-26 | $204.67M derived: sum of 3 quarters · filed 2013-02-26 | $205.82M 10-K · filed 2013-02-26 | |||
| 2010-09-30 | $217.33M 10-Q · filed 2011-10-31 | $216.86M derived: sum of 2 quarters · filed 2011-10-31 | $218.01M 10-Q · filed 2011-10-31 | ||||
| 2010-06-30 | -$477.00K 10-Q · filed 2011-08-01 | $674.00K 10-Q · filed 2011-08-01 | |||||
| 2009-12-31 | -$488.00K 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |